Compare SPB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPB | DFTX |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | SPB | DFTX |
|---|---|---|
| Price | $83.72 | $24.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $82.40 | $38.50 |
| AVG Volume (30 Days) | 326.4K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $38.81 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $14.62 |
| 52 Week High | $86.96 | $26.25 |
| Indicator | SPB | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 61.13 |
| Support Level | $72.94 | $16.37 |
| Resistance Level | $86.23 | $25.71 |
| Average True Range (ATR) | 2.35 | 1.48 |
| MACD | 0.59 | 0.06 |
| Stochastic Oscillator | 84.76 | 84.73 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).